Article

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients: From Bedside to Bioinformatics.

2020-12-01

Abstract excerpt

<h4>Background: </h4> The primary nonresponse (PNR) rate of Infliximab (IFX) varies from 20% to 46% for the treatment of Crohn’s disease (CD). Detected PNR reduces the improper use of specific treatments. To date, there is hardly any knowledge regarding early markers of PNR. The aim of this study was to evaluate the role of Interleukin-6 (IL-6) as an early predictor of PNR of IFX for the treatment of CD. <h4>Metho...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cff13730-e18f-51f8-8260-96888fddeaf7
DOI: 10.22541/au.160681175.57331828/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients: From Bedside to Bioinformatics.DOI 10.22541/au.160681175.57331828/v1Read

To evaluate the predictive effect of vitamin D on clinical outcomes of infliximab treated Crohn’s disease patients in western ChinaSemantic proximity Read

A Novel Nomogram for Predicting Mucosal Healing in Crohn's Disease in ChildrenSemantic proximity Read

Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile.Semantic proximity Read

Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn’s disease patientsSemantic proximity Read

The CCL2/CCR2 axis is related to primary non-response to infliximab therapy in patients with Crohn’s diseaseSemantic proximity Read

Hyperactive chemotaxis contributes to anti-TNFα treatment resistance in inflammatory bowel diseaseSemantic proximity Read

[Relationships of interleukin-7 receptor gene polymorphisms with the risk of Crohn's disease and the efficacy of infliximab].Semantic proximity Read

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.Semantic proximity Read

Characterisation of 3000 patient reported outcomes with predictive machine learning to develop a scientific platform to study fatigue in Inflammatory Bowel DiseaseSemantic proximity Read

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative ColitisSemantic proximity Read

Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn’s Disease Using Transcriptome Imputed from GenotypesSemantic proximity Read